A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. Background: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results